Management of stable patients with coronary heart disease: Clinical implications of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial

Journal of Clinical Lipidology

Volumn 1, Issue 6, 2007, Pages 564-574

  Brown, Todd M ^a,b   Bittner, Vera ^a  

^a University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Angina; Coronary artery disease; COURAGE trial; Myocardial infarction; Percutaneous coronary intervention; Risk factor modification

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANGINA PECTORIS AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FIBRIC ACID DERIVATIVE; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE MONONITRATE; LISINOPRIL; LOSARTAN; METOPROLOL; MEVINOLIN; NICOTINIC ACID; NITRATE; PERINDOPRIL; PLACEBO; SIMVASTATIN; WARFARIN;

AEROBIC EXERCISE; ANGINA PECTORIS; CANADA; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEATH; DIABETES MELLITUS; DIET; DRUG EFFICACY; DRUG HYPERSENSITIVITY; EARLY INTERVENTION; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART REHABILITATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LOW FAT DIET; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; THERAPY EFFECT; TREATMENT OUTCOME; UNITED STATES;

ANGINA;

EID: 36849083622     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2007.10.009     Document Type: Review

References (53)

1. Rosamond W., Flegal K., Friday G., et al. Heart Disease and Stroke Statistics-2007 Update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
2. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction) (2004) Available at www.acc.org/clinical/guidelines/stemi/index.pdf.
3. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College of Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 50 (2007) e1-e157
4. Gibbons R.J., Abrams J., Chatterjee K., et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients with Chronic Stable Angina). 2002. Available at. www.acc.org/clinical/guidelines/stable/stable.pdf
5. Lin G.A., Dudley R.A., and Redberg R.F. Cardiologists' use of percutaneous coronary interventions for stable coronary artery disease. Arch Intern Med 167 (2007) 1604-1609
6. Feldman D.N., Gade C.L., Slotwiner A.J., et al. Comparison of outcomes of percutaneous coronary interventions in patients of three age groups (<60, 60 to 80, and >80 years) (from the New York State Angioplasty Registry). Am J Cardiol 98 (2006) 1334-1339
7. Boden W.E., O'Rourke R.A., Teo K.K., et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356 (2007) 1503-1516
8. Wharton Jr. T.P., Umans V.A., and Peels H.O. PCI for stable coronary disease. N Engl J Med 357 (2007) 415
9. Katritsis D.G., and Ioannidis J.P. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation 111 (2005) 2906-2912
10. The Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group. Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. N Engl J Med 311 (1984) 1333-1339
11. Coronary Artery Surgery Study (CASS) Principal Investigators and Associates. CASS: a randomized trial of coronary bypass surgery. Circulation 68 (1983) 939-950
12. Varnauskas E., and European Coronary Surgery Study Group. Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. N Engl J Med 319 (1988) 332-337
13. Yusuf S., Zucker D., Peduzzi P., et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 344 (1994) 563-570
14. Hoffman S.N., TenBrook Jr. J.A., Wolf M.P., Pauker S.G., Salem D.N., and Wong J.B. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one- to eight-year outcomes. J Am Coll Cardiol 41 (2003) 1293-1304
15. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 335 (1996) 217-225
16. The BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 96 (1997) 1761-1769
17. Freemantle N., Cleland J., Young P., Mason J., and Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 318 (1999) 1730-1737
18. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
19. The EURopean Trial. On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
20. Rossouw J.E. Lipid-lowering interventions in angiographic trials. Am J Cardiol 76 (1995) 86C-92C
21. Rodriguez-Granillo G.A., Agostoni P., Garcia-Garcia H.M., et al. Meta-analysis of the studies accessing temporal changes in coronary plaque volume using intravascular ultrasound. Am J Cardiol 99 (2007) 5-10
22. Nicholls S.J., Tuzcu E.M., Sipahi I., et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297 (2007) 499-508
23. O'Keefe J.H., Cordain L., Harris W.H., Moe R.M., and Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl. J Am Coll Cardiol 43 (2004) 2142-2146
24. Buchwald H., Matts J.P., Fitch L.L., et al. Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group. JAMA 268 (1992) 1429-1433
25. Brown B.G., Zhao X.-Q., Sacco D.E., and Albers J.J. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 87 (1993) 1781-1791
26. Schuler G., Hambrecht R., Schlierf G., et al. Regular physical exercise and low-fat diet: effects on progression of coronary artery disease. Circulation 86 (1992) 1-11
27. Gould K.L., Matucci J.P., Goldberg D.I., et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. Circulation 89 (1994) 1530-1538
28. Falk E., Shah P.K., and Fuster V. Coronary plaque disruption. Circulation 92 (1995) 657-671
29. Libby P. What have we learned about the biology of atherosclerosis?. The role of inflammation. Am J Cardiol 88 suppl (2001) 3J-6J
30. Taylor R.S., Brown A., Ebrahim S., et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 116 (2004) 682-692
31. Witt B.J., Jacobsen S.J., Weston S.A., et al. Cardiac rehabilitation after myocardial infarction in the community. J Am Coll Cardiol 44 (2004) 988-996
32. Wilt T.J., Bloomfield H.E., MacDonald R., et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 164 (2004) 1427-1436
33. Afilalo J., Majdan A.A., and Eisenberg M.J. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart 93 (2007) 914-921
34. Hambrecht R., Walther C., Mobius-Winkler S., et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease. Circulation 109 (2004) 1371-1378
35. Pitt B., Waters D., Brown W.V., et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 341 (1999) 70-76
36. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 336 (1997) 153-162
37. Knatterud G.L., Rosenberg Y., Campeau L., et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the Post Coronary Artery Bypass Graft Trial. Circulation 102 (2000) 157-165
38. Sdringola S., Nakagawa K., Nakagawa K., et al. Combined intensive lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usual-care cholesterol-lowering drugs in coronary artery disease. J Am Coll Cardiol 41 (2003) 263-272
39. Sdringola S., Loghin C., Boccalandro F., and Gould K.L. Mechanisms of progression and regression of coronary artery disease by PET related to treatment intensity and clinical events at long-term follow-up. J Nucl Med 47 (2006) 59-67
40. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
41. Shah A.P., Shavelle D.M., and French W.J. PCI for stable coronary disease. N Engl J Med (2007) 357-415
42. Kiat H. PCI for stable coronary disease. N Engl J Med (2007) 357-416
43. Shaw L.J., Heller G.V., Casperson P., et al. Gated myocardial perfusion single photon emission computed tomography in the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial, Veterans Administration Cooperative study no. 424. J Nucl Cardiol 13 (2006) 685-698
44. Nagajothi N., Velazquez-Cecena J.-L., and Khosla S. PCI for stable coronary disease. N Engl J Med 357 (2007) 416-417
45. Boden W.E., Teo K.K., and Weintraub W.S. PCI for stable coronary disease. N Engl J Med 357 (2007) 417-418
46. Kereiakes D.J., Teirstein P.S., Sarembock I.J., et al. The truth and consequences of the COURAGE trial. J Am Coll Cardiol 50 (2007) 1598-1603
47. Weintraub W.S. Presented at the American College of Cardiology Annual Scientific Sessions, New Orleans, LA, March 2007. Available at. http://www.medscope.com/viewarticle/554223 November 12, 2007
48. Kereiakes D.J. PCI is no better than medical therapy for stable angina?. Seeing is not believing. Cleve Clin J Med 74 (2007) 637-642
49. Boden W.E. It takes COURAGE to alter our belief system. Cleve Clin J Med 74 (2007) 623-633
50. The BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol 49 (2007) 1600-1606
51. Ford E.S., Ajani U.A., Croft J.B., et al. Explaining the decrease in US deaths from coronary disease, 1980-2000. N Engl J Med 356 (2007) 2388-2398
52. DeServi S. PCI for stable coronary disease. N Engl J Med (2007) 357-416
53. Mak K.-H. PCI for stable coronary disease. N Engl J Med (2007) 357-417